Elutia Q3 revenue falls short of estimates, gross margin improves

Elutia

06/11/2025 22:32

Overview

Elutia Q3 revenue missed analyst expectations

Company completed $88 mln sale of BioEnvelope business to Boston Scientific

Gross margin improved to 55.8% from 48.9% in Q3 2024

Outlook

Elutia anticipates FDA clearance for NXT-41x base matrix in 2H26

Company expects drug-eluting NXT-41x version clearance in 1H27

Result Drivers

BIOENVELOPE SALE - Sale of BioEnvelope business to Boston Scientific for $88 mln used to eliminate debt and fund NXT-41x development

NXT-41X DEVELOPMENT - Advancing NXT-41x to address infections in plastic and reconstructive surgery, targeting a $1.5 bln market

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$3.32 mln
$6.65 mln (2 Analysts)
Q3 Net Income
-$3.87 mln
Q3 Gross Profit
$1.85 mln
Q3 Income From Operations
-$5.21 mln
Q3 Operating Expenses
$7.06 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Elutia Inc is $4.00, about 76% above its November 5 closing price of $0.96

Press Release: ID:nGNX4njjLm

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)